Caliper Life Sciences has announced the availability of its General Side Effects Profile (Gensep) service to assess the potential for safety liabilities of drugs under Good Laboratory Practices (GLP).
The service will be offered through the Caliper Discovery Alliances and Services (CDAS) unit.
The ability to offer these services under GLP enhances the acceptance of data when included in the drug candidates' regulatory filings.
'However, the adoption of laboratory practices under full GLP compliance provides CDAS's customers with the option to perform an even greater level of quality assurance with our pre-clinical safety and predictive toxicity studies,' said David Manyak, executive vice-president, Drug Discovery Services of Caliper Life Sciences.
'The ability to operate under GLP also facilitates CDAS's growing expansion in biomarker studies, allowing us to analyse clinical trial samples in addition to our pre-clinical biomarker detection activities, moving Caliper further towards personalised medicine,' he added.